Скачать или смотреть Revolutionary Tumor Vaccines for Pancreatic Cancer: 2025 Clinical Trials Explained

Pancreatic cancer remains one of the deadliest malignancies, but groundbreaking clinical trials in 2025 are testing personalized tumor vaccines, including mRNA-based, neoantigen-targeted, and KRAS-directed platforms. These trials, conducted in leading centers in China and the United States, aim to overcome the immune-cold nature of pancreatic tumors by inducing durable, tumor-specific T-cell responses. This video explores the most promising active and recruiting trials, including:
mRNA and Neoantigen-Based Vaccine Trials
Study of Neoantigen mRNA Vaccines in Resectable Pancreatic Cancer (NCT06326736)
Personalized Tumor Vaccines and Pembrolizumab in Advanced Pancreatic Cancer (NCT05916261)
XH001 Neoantigen Cancer Vaccine With Immunotherapy and Chemotherapy After Surgery (NCT06353646)
Neoantigen Vaccine Plus Anti–PD-1 and Chemotherapy as Adjuvant Therapy (NCT06344156)
mRNA Vaccine Plus PD-1 Inhibitor as Adjuvant Therapy After Surgery (NCT06496373)
Individualized mRNA Neoantigen Vaccine in Advanced Endocrine and Pancreatic Neuroendocrine Tumors (NCT06141369)
KRAS-Targeted Vaccine Trials
KRAS Neoantigen mRNA Vaccine in KRAS-Mutated Solid Tumors (NCT06577532)
Neoadjuvant and Adjuvant GVAX vs mKRASvax With Anti–PD-1 and Anti–CD137 (NCT06782932)
Mutant KRAS–Targeted Long Peptide Vaccine in High-Risk Individuals (NCT05013216)
KRAS-Targeted Vaccine With Balstilimab and Botensilimab (NCT06411691)
Each trial is explained in detail, including its objectives, design, and potential impact on pancreatic cancer treatment. Stay informed about the latest advancements in personalized immunotherapy for this challenging disease.